$RGA

Munich Re and Lloyd’s move to the top of AM Best’s global reinsurer rankings

AM Best’s year-end 2025 rankings for global reinsurers put Munich Re back at No.1 among IFRS 17 reporters, with gross reinsurance revenue of $35.418 billion, ahead of Swiss Re at $34.564 billion. For non-IFRS 17, Lloyd’s moved to No.1 with GPW of $27.058 billion, ahead of Berkshire Hathaway at $25.470 billion. AM Best cited underwriting strength, capital levels, FX effects, and hurricane activity.

Original reporting
Published Aug 17, 2026, 5:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 17, 2026, 5:53 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Munich Re and Lloyd’s move to the top of AM Best’s global reinsurer rankings — source image
Decision brief

The 30-second read

$RGANeutralLow
01

Why it matters

The main tradable takeaway is relative positioning: Munich Re regains the IFRS 17 lead, while Lloyd’s moves above Berkshire Hathaway in the non-IFRS 17 table, with FX and premium growth cited as key drivers.

02

Market read

This is a sector positioning update grounded in year-end 2025 data, with FX and catastrophe assumptions highlighted, but it does not provide new forward guidance or fresh company-specific disclosures.

03

What to watch

The piece notes third-party capital and ILS structures could affect premium-based rankings, meaning balance-sheet underwriting capacity and future profitability may not track rank changes.

Relevance 4/10Novelty 4/10Timing: today’s publication of AM Best’s year-end 2025 ranking update

Background

AM Best ranks reinsurers differently depending on whether they report under IFRS 17 or non-IFRS 17, using gross reinsurance revenue or gross written premium (GPW).

Company-level read

Ticker impact

$RGANeutralHigh confidence
Context

AM Best’s non-IFRS 17 rankings show Reinsurance Group of America (RGA) maintaining third place with GPW of $17.482B.

Expected impact

Negligible immediate impact; likely no tradable catalyst from a static ranking position.

Evidence & confidence

The text provides a datapoint (GPW and rank) without new operational, regulatory, or guidance information.

$RNRNeutralHigh confidence
Context

RenaissanceRe is shown as fifth in the non-IFRS 17 rankings with GPW of $11.738B.

Expected impact

Negligible near-term impact.

Evidence & confidence

This is a static ranking datapoint rather than a new catalyst.

$ACGLNeutralHigh confidence
Context

Arch Capital is listed sixth in the non-IFRS 17 table with GPW of $27.058B for Lloyd’s above, and Arch Capital at sixth.

Expected impact

Negligible trading impact.

Evidence & confidence

The article does not describe any Arch Capital-specific event, guidance, or regulatory development.

Market effects

Highlights continued underwriting strength in 2025, record capital generation, and the role of hurricane absence plus convective storm losses, which can influence sector sentiment.

US-specific weather discussion (no major hurricane landfall, but convective storm losses up to $61B) reinforces US catastrophe risk pricing narratives.

FX translation (EUR and GBP strength vs USD) is emphasized as a driver of cross-firm comparability, relevant for global reinsurer earnings interpretation.

Counterpoint

Because the article is a ranking based on year-end 2025 figures and heavily attributes differences to FX and methodology (IFRS 17 vs non-IFRS 17), it may not reflect forward underwriting or capital changes.

Key entities

  • Munich Re

    Reclaimed #1 in AM Best’s IFRS 17 reinsurer ranking on 2025 gross reinsurance revenue of $35.418B.

  • Lloyd’s

    Moved above Berkshire Hathaway to claim top spot for non-IFRS 17 reinsurers on 2025 GPW.

  • Berkshire Hathaway

    Dropped to #2 in the non-IFRS 17 ranking as Lloyd’s outpaced it on GPW growth and FX effects.

  • Swiss Re

    Ranked #2 in IFRS 17 with gross reinsurance revenue down 4.5% to $34.564B, with FX noted in the comparison.

  • AM Best

    Published the ranking methodology and commentary on underwriting performance, capital levels, and catastrophe impacts.

Related articles

$ACGLHighAI 8/10

Arch Capital Q3 2026 slides: 25 years of superior returns, 82% combined ratio

Arch Capital Group (ACGL) reported Q3 2026 earnings, highlighting 25 years of operations, $22.8B in gross premiums, and an 82.1% combined ratio. The company showed strong financial metrics, including $27.3B in total capitalization and AA- and A+ ratings. Shares rose 2.95% to $103.39 post-earnings. Arch emphasized its disciplined underwriting, diversification, and conservative investment strategy, which contributed to superior risk-adjusted returns.

$ACGLMed

Citizens reaffirms Arch Capital stock rating on strong results

Citizens reaffirmed a Market Outperform rating and $125 price target for Arch Capital Group (ACGL) after its Q3 2026 results beat expectations. The company reported adjusted EPS of $2.67 and revenue of $5.39 billion, but net premiums earned declined 6.3% year-over-year. Citizens cited strong market positioning and conservative management as key strengths.

$RNRMed

RenRe posts $161m loss as bond values fall

RenaissanceRe reported a Q3 net loss of $161.4M, down from a $907.7M profit last year, due to bond value declines. Underwriting income fell to $426.1M, and the combined ratio worsened to 79.7%. CEO Kevin O’Donnell highlighted strong underwriting, fee income, and investment income, expecting higher yields to benefit future returns. Book value per share decreased 1.9% to $259.61.

$ACGLHighAI 8/10

Why is Arch Capital stock climbing today?

Arch Capital (ACGL) stock rose 1.3% after-hours after Q3 earnings beat expectations, with adjusted EPS of $2.67 vs. $2.30 estimate and revenue of $5.39B vs. $4.06B. CEO noted strong underwriting and investment performance. Combined ratio was 82.5%, and $1.4B in shares were repurchased. Net income declined YoY to $1.0B due to catastrophe losses. Analysts' price target is $108.39.